Eli Lilly & Co. investors have been eagerly awaiting more details on the investigational dual GIP and GLP-1 receptor agonist tirzepatide for type 2 diabetes, but while new Phase II data presented at the American Diabetes Association Scientific Sessions, showed an improvement, it did not alleviate concerns about tolerability.
Lilly announced incremental data from four separate studies of tirzepatide, which showed improvements in markers of beta-cell function and insulin sensitivity. Data from a 12-week Phase II study showed efficacy and improved tolerability with lower initial doses and smaller subsequent dose escalations than what was seen in a Phase IIb study reported last year
